INDEX

A C

Abnormal ova, 351 -352 Cancer chemotherapy, cannabis as antiemetic

ACTH, 373 in, 10-11
3
H - A D T N binding, measurement of, 578-586Cannabidiol, 177
Aldehyde intermediate, cyclization of, 140 anticonvulsant activity of, 533
Ames Salmonella/microsomal bioassay anxiolytic effects of, 795-811
system, 771-772 deuterium-labeled, 221 -222
Angel dust, see Phencyclidine hydrochloride generalization tests with, 556
Anticonvulsants, 14, 525-527, 778-780 in glaucoma therapy, 875 -876, 881-889
Antiglaucoma agents, 786-788 pharmacological activity of, 534
Antineoplastic activity, cannabis/argenine plasma levels of, 222-223
interaction and, 687-688 single-dose kinetics of, 219-224
Axiolytic effects, 795-811 tremor and seizure activity reduction by,
experiments in, 796-808 796-809
Arachidonic acid release, PGE synthesis and, Cannabidiolic acid-tetrahydrocannabitriol
736 ester, 92
Arginine, spermatogenesis and, 672 Cannabinoid analysis of body fluids
Arginine/cannabis interactions, see Cannabis/ chemical process automation in, 156-158
argenine interactions conjugates and radioligands for, 137
Argenine utilization/metabolism, cannabis forensic applications of, 123-132
interference with, 671 -693 solid phase synthesis in, 158-159
Aspirin, inhibition of THC-induced hypoten- Cannabinoids, see also Tetrahydrocannabinol
sion by, 731 acidic, 206
acid/neutral separation in, 79-88
A C T H activity and, 373
anticonvulsant activity and, 14, 525-527,
Β 778-780
antiemetic properties of, 859-869
Behavioral reactivity, T H C and, 567-570 as antiglaucoma agents, 786-788
Beta-adrenergic receptor, T H C interaction brain amine concentrations and, 415-418
with, 591-600 behavioral effects of, 866-868
6-Beta-hydroxy-delta-1-THC, synthesis of, 73 behavioral pharmacogenetic studies of,
Blood platelets, hashish smoking and, 674 829-840
Blood pressure, 636 beta receptor and, 576
Blue formazan production, 334-336 blood pressure and body temperature
Body temperature effects, 636-639, 643 effects of, 636-640
Bradycardia, 635 brain levels of in percent of total radioacti-
Brain anine concentrations, 415, 418 vity administered, 723
Brain monoamine metabolism, 617 brain norepinephrine and, 422
Brain neuroreceptors, 575-586 brain neurotransmitter receptors and,
Brain norepinephrine, 422 575-586

901
902
cardiovascular response to. 641
in catecholaminergic neurotransmission,
575-576
central sensory processing and, 621-631
chemistry and structure-activity relation-
ships of. 63-76
classification of, 89
CNS effects of. 411-422
cumulative excretion of. 232
in discriminative stimulus studies, 545-559
extraction from leaves. 80
fractionation and isolation from cannabis
extract, 605
gas-liquid chromatography of, 80-81,
85-86
in glaucoma therapy, 12, 786-788,
871-879, 881-889
heated samples of, 83-85
high-performance liquid chromatography
of, 80-82
human brain M A O and, 613
human liver M A O and, 614-616
in human plasma, 169-170, 174, 177-182
hypothalamic amine concentrations and,
416
in monkey behavioral tests, 785
monoamine oxidase and, 604-616
mouse behavioral activity and, 524-525
neurotransmitter levels and reproductive ef-
fects of, 411-422
novel derivatization methods in analysis of,
151-160
numbering systems used in, 64
and overt behavior in dogs, 525-526
pharmacological activity of, 523-541
pig brain M A O and, 606-612
pig liver M A O and, 612
polyhydroxylated, 90
prostaglandins and, 729-736
psychotropic and analytic effects of,
780-784
pyran ring for analgetic activity of, 788
semisynthetic, see Semisynthetic
cannabinoids
simultaneous intravenous and oral
administration of, 227-237
solvent pH in chromatography of, 83
spermatogenesis and, 427-436
3 3
inH-spiperone and H - A D T N binding,
577-586
structure-activity relationships in, 74-76,
523
synthesis of, 63-69, 524-525
Index
teratogenesis and, 420
testicular concentrations and, 414
testosterone propionate implants and,
404-407
as therapeutic agents, 524, 777-790
urinary and fecal excretion of, 123- 132,
192-198,214-215,232-234,263-278
Cannabinol, 177
Cannabinol derivatives, in dog static ataxia
test, 535-540
Cannabiripsol, 92
Cannabis, see also Marijuana; Tetrahydrocan-
nabinol
brain macromolecular synthesis and, 690
cellular transcription inhibition by, 672
G A B A and, 691-692
interference with arginine utilization and
metabolism, 671 -693
Cannabis/arginine interactions, 671 -693
carcinogenicity and antineoplastic activity
in, 687-688
chromosome aberrations and immune
functions in, 682-687
immunological defects and, 683-686
macromolecular synthesis and, 678-681
muscle and nerve in relation to, 688-692
steroids, lipoproteins, and cholesterol in,
681-682
Cannabis components, monoamine oxidase
and, 603-619
Cannabis extract, fractionation and isolation
of cannabinoids from, 605
Cannabis psychosis, 4
Cannabis sativa L.
constituents of, 89-96
Panamanian variant of, 94
separation of acid and neutral cannabinoids
in, 79-88
Cannabis use, see also Marijuana cigarette
smoking
as analgesic, 13, 781-782
in angina patients, 7
as anticonvulsive, 14
as antiemetic in cancer chemotherapy,
10-11
brain damage from, 5-6
in bronchial asthma, 14
cardiovascular problems and, 7
cell metabolism and, 9
chronic, 4
chromosomal abnormalities and, 9
contaminants and, 9
drug accumulation in, 9
Index
endocrine and metabolic effects of, 8
in glaucoma patients, 12-13, 786-788,
871-879, 881-889
health aspects of, 3-16
in hypertension, 15
in hypotension, 635, 731, 822-823
immunity and, 9
in insomnia, 14- 15
lung problems in, 7
memory functioning and, 21 -43
as muscle relaxant, 13-14
in pregnancy and fetal development, 8-9
psychopathology of, 4
therapeutic uses of, 10-15, 781-788,
871-879, 881-889
tolerance/dependence in, 6
Cannabitriol, 91-92, 95
Cannabitetrol
isolation of, 93
N M R spectrum of, 95
physical characteristics of, 94
Carbon dioxide production, from rat
testicular tissue, 457-462
Carcinogenicity, cannabis/arginine interaction
and, 687-688
Cardiovascular response, 640-641
Castrated rats, gonadotropin levels in, 407,
see also Rat(s)
Cat behavior, intravenous T H C and, 868
Catecholaminergic neurotransmission,
cannabinoids in, 575-576
Cats
blood pressure and body temperature
effects in, 636-639, 643
cisplatin vomiting in, 857-869
cortical sensory evoked activity in, 621 -
631
Cat spinal monosynaptic reflex, 851-852
CBD, see Cannabidol
CBN, see Cannabinol
Cellular transcription, inhibition of, 672
Centrifichem Creatinine Assay kit, 282
Central nervous system, electrically evoked
activity in sensory areas of, 622-625
Central nervous system lesions, female rat
prolactin levels and, 497 - 518
Central nervous system neurotransmitter,
marijuana effect on, 411 -422
Central sensory processing, cannabinoids and,
621-631
Chemical processes, automation of, 156-158
Chemotherapy, cannabis as antiemetic in,
10-11
903
Chocolate cookies, marijuana in, 167, 170,
175, 177, 212
Cholesterol
in adrenal gland, 681
T H C and, 682
Chromosome aberrations
cannabis/arginine interactions and,
682-687
marijuana smoking and, 683-684
Chrysanthenol, T H C from, 66-67
Cigarettes, marijuana, see Marijuana cigarettes
Cigarette smoking machines, 97-100
Cisplatin vomiting, T H C antiemetic properties
in, 859-869
C M E , see Crude marijuana extract
Cobalt epilepsy technique, 846-850
Complete hypothalamic deafferentation, T H C
effects in, 507-509
Convulsant actions
electrophysiological mechanisms in,
845-846
in rabbits, 829-840
Cortical sensory evoked activity, T H C
electrophysiological effects on, 621-631
Creatinine study, in marijuana cigarette
smoking, 274-277, 282
C-ring substitutions, alterations in, 532
Crude marijuana extract, male rat sex organs
and, 401-409
D
2-Deoxy-D-glucose, glucose uptake experi-
ments with, 456-457
Diagonal band of Broca sections, T H C and,
511
Diethyl stilbestrol bisphosphate, argininyl
residues and, 681
Dihydroxyacetone phosphate, analysis of, 456
3
H-Dihydroalprenolol binding, T H C effect
on, 593-598
Dimethylheptylpyran, in visual and somato-
sensory evoked potentials, 622, 627
Discriminative stimulus properties, of THC,
545-559
Dogs
cannabinoid effect on behavior of, 525-526
fractional sodium and potassium excretion
in, 739-748
THC-induced hypotension in, 730
Dog static ataxia test, 535-540
904 Index

Dorsal longitudinal fasciculus sections, T H C Glycolytic intermediates, destination of, 456

effects in, 513 Gonadotropin releasing hormone, PCP and,
Drug abuse treatment programs, marijuana 450
users' characteristics and outcomes in, Gynecomastia, marijuana and, 386
47-58

H
Ε

Haloperidol- and chlorpromazine-induced

Electroshock, anticonvulsant activity against,
hypokinesia, 820-823
525
Hashish extract
EMIT (enzyme immunoassay) urinalysis
human brain M A O and, 613
system, in T H C urine analysis, 123- 132,
human liver M A O and, 614-616
274-278, 281-289
pig brain M A O and, 606-612
Erythrocytes, marijuana smoking effects in,
T H C inhibitory effect and, 608
674-676
Hashish smoking, blood platelets and, 674,
Estradiol, benzylation of, 154-155
see also Marijuana cigarette smoking
Estradiol benzoate
Herpes simplex virus replication, T H C and,
in rat reproductive development and
891-898
function, 385-396
1 l-nor-/?-OH-Hexahydrocannabinol, T H C
in rat seminal vesicle and prostate, 359-379
responses and, 557
rat testis and, 385-396
"High/' from T H C use, 191, 245-258
rat ventral prostate and, 369-379
Human brain monoamine oxidase, cannabin-
Ethanol
oid and hashish extract effects on,
blue formazan production in, 334-336
613-614
in C 0 2 production from rat testicular
Human liver monoamine oxidase, cannabin-
tissue, 457-462
oid and hashish extract effects on,
nitro blue tetrazolium reduction by,
614-616
319-325
7-Hydroxy-delta-2-THCs, synthesis of,
in superoxide radical generation, 319-325
70-71, see also Tetrahydrocannabinol
T H C absorption spectrum in, 330-332
Hydroxymetabolites, cross reaction of
Excitatory postsynaptic potentials, 849-856
1 l-hydroxy-delta-8-THC antiserum with,
Extrapyramidal motor behaviors, in Parkin-
145-146
son's disease model, 815 - 827
1 l-Hydroxy-delta-8-THC
development of antiserum to, 143- 144
F synthesis of, 139-141
1 l-Hydroxy-delta-9 T H C
analysis of plasma from, 147-148
Female rats, serum prolactin levels in,
497-518, see also Rat(s) radioimmunoassay for, 135-148
Follicle stimulating hormone, 472-475 Hypokinesia, response-induced, 816-819
Follicular phase, T H C effects in, 476 Hypotension
Forensic applications, of cannabinoid analyses aspirin in inhibition of, 731
in body fluids, 123-132 haloperidol- and chlorpromaxine-induced,
Frontal suprachasmic cuts, T H C effects in, 509 822-823
T H C and, 635, 730
Hypothalamic amine concentrations, 416
G

G A B A (gamma-aminobutyric acid), 691 -692 I

Glaucoma, 12, 786-788, 871-879, 881-889
D-Glucose-6-phosphate, analysis of, 456 Immunosuppression, cannabis-induced, 686
Glucose utilization, 464 Inhibitory postsynaptic potential, 849-856
Index
L characteristics of, 111
Ligand/liquid biphasic benzylation reactions,
152-156
Luteal corticohypothalamic tract sections,
T H C effects in, 510
Luteal phase, T H C effects in, 479
Luteinizing hormone
PCP injection and, 447-450
T H C and, 472-475
M tetrahydrocannabinol absorption in,
Macromolecular synthesis, 429
Male mice, reproductive function effects of
cannabinoids in, 411 -422, see also Mice; Marijuana use, see also Marijuana cigarette
Mouse
Male rat accessory gland, fructose formation
in, 464, see also Rat(s)
Male rat sex organs, cannabinoid treatment
effect on androgenic stimulation of,
401-409
Male reproductive function, marijuana effect
on, 453-467, see also Reproductive
function
M A O , see Monoamine oxidase
Marijuana, see also Cannabinoids; Cannabis;
Marijuana cigarettes; Tetrahydrocanna-
binol
in chocolate cookies, 167, 170, 175, 177,212 and state dependent learning, 35
defined, 97
gynecomastia and, 386
impotence and, 411
objective and subjective effects of, 829-831
PCP and, 441
reduced sperm count and, 411
reproductive function and, 346, 427-436,
453-457, 471-483
Marijuana cigarettes
defined, 97
gas-liquid Chromatograph studies of, 96,
100-101
humidification of, 108
moisture content in, 101-103
nonuniform density of, 112
preparation of, 99
puff volume profile for, 112-113
puff volume transducer for, 113-114
smoking characteristics of, 97-108
T H C content in, 101-106
Marijuana cigarette smoking, see also
Marijuana use
905
chromosomal aberrations and, 683-684
creatinine study in, 277-21'4
dynamics of, 111-121
erythrocytes in, 614-61 β
heavy and light users in, 166, 171
"high" in, 191,245-258
radiolabeling in analysis of, 166-167
reproductive function and, 346, 427-436,
453-457, 471-483
steady state T H C blood levels in, 126-127
system performance in, 117 -120
239-242
urinary excretion patterns in, 123-132,
263-268, 281-289
smoking
changes in, during Treatment Outcome
Prospective Study, 57
delayed free recall test and, 30
high from, 191, 245-258
human memory and, 21 -43
immediate free recall test and, 29-30
incidence of, U.S., 48-50
lifetime prevalence in, 49
number of words recalled in, 31-34
pulse rate changes in, 28
recognition memory and, 40
restricted reminding technique and, 41-42
urinalyses for, 123-132, 263-278, 281-289
visual/mental memory and, 36-37
Marijuana users
admission characteristics of, 51-55
characteristics, behaviors and outcomes for,
in treatment program, 47-58
intreatment performance of, 55-57
"light" vs. "heavy," 253
T H C concentrations vs. "high" in, 245-248
Mediobasal hypothalamus, PRL release and,
513-518
Memory functioning, 21-43
smoking technique and, 25-26
Memory system, structure of, 23
Menstrual cycle hormones, T H C effects on,
471-483
p-Menthadienol, T H C from, 67-69
p-Menth-2-ene-l,8-diol, T H C from, 68
Methionine, substitution of with THC, 334,
338-339
Monkey behavioral tests, analgesia and, 785,
see also Rhesus monkey
906
Monkey intraocular pressure, cannabinoid
effects on, 871-879
Monoamine oxidase
brain monoamine metabolism and, 617
cannabis and, 603 - 619
chloroformic extraction of, 605
Lineweaver-Burk plots for, 610
Mouse, see also Mice
behavioral reactivity in, 567-570
normal and abnormal gestational products
in, 348-349
spontaneous activity and body temperature
in, 524-525
Mouse analgesia tests, 785
Mouse decreased food intake, T H C and,
563-572
Mouse embryo development, T H C and,
345-353
Mouse enhanced reactivity, T H C and,
563-572
Mouse erythrocytes, T H C levels in, 305
Mouse spermatogenesis, cannabinoid effects
in, 427-436
Muscle, cannabis/arginine interaction and,
688-692
Ν Primate menstrual cycle, THC, and, 478-
National Institute on Drug Abuse, 360
NBT, see Nitro blue tetrazolin
Nervous system, cannabis/arginine interaction Prolactin levels
and, 688-692, see also Central nervous
system
Neurotransmitter levels, cannabinoid effects Prolactin secretion
on, 411-422
Neurotransmitters, cannabinoid-induced
changes in, 411 -412
Nitro blue tetrazolin
pathway of in T H C reduction, 331
for photoreduction ofriboflavin,335
reduction of by ethanol, 319-325
substitution of with THC, 334, 337-338
Nucleus accubens, T H C injections in,
649-654
Ο Rabbits
Opioid activity augmentation, T H C and,
788-790
Ova degeneration, 351-352
Oxepine derivatives, 529
Index
Ρ
Parkinson's disease model, extrapyramidal
motor behaviors in, 815 - 827
Phase transfer analysis, schematic of, 153
Phase transfer catalysis, in cannabinoid
analysis, 151 - 160
Phencyclidene hydrochloride
luteinizing hormone and, 447-450
rat sex hormone levels and, 441 -450
Phenols, pentafluorobenzylation of, 157
Pig brain monoamine oxidase, cannabinoids
and hashish extract effects on, 606-612,
618
Pig liver monoamine oxidase, cannabinoid
and hashish extract effects on, 612
Plasma levels
"high" and "low," 245-258
pharmacologic effect and, 177-182,
189-195, 205, 222, 229-231
quantitation of, 189-192, 293
Potassium chloride, striatum inactivation
and, 823-827
Presuprachiasmatic cuts, T H C effects in,
509-510
Primary human epithelium, virus cytopathic
effects in, 893
482
Progesterone production, marijuana, and,
474
in CNS-lesioned feral rats, 497-518
T H C and, 482
mediobasal hypothalamus and, 513-518
suckling-induced, 487-494
Prostaglandins, cannabinoid action and,
729-736
Prostaglandin synthesis, arachidonic acid
release and, 736
Pyran ring, in cannabinoid analgetic activity,
788
R
cannabinoid-induced convulsions in,
834-837
glaucoma therapy in, 884-889
THC-seizure-susceptible, 829-840
Radioimmunoassays, 135-148
Index
Radiolabeled cannabinoids, 187, 712
Rat(s)
cobalt epileptic, 846-850
discriminative stimulus studies of, 545-559
excitatory electrophysiological effects in,
846-851
kindled limbic seizures in, 848
Rat accessory sex organs, cannabinoid effects
in, 401-409
Rat brain
locomotor activity and, 649-654
T H C recovered in, 313-314
Rat locomotor activity, T H C effects in,
649-654
Rat reproduction development, T H C and
estradiol benzoate effects on, 385-396
Rat seminal vesicle, estradiol benzoate and
T H C effects on, 359-379
Rat sex hormone levels
phenyclidine and, 441 -450
T H C injections and, 441-450
Rat spleen, T H C recovered from, 316
Rat testicular tissue, 2-deoxy-D-glucose
uptake by, 463
Rat testis
T H C and estradiol benzoate effects in,
385-396
T H C recovered from, 313-314
Rat tissues, T H C distribution and disposition
by, 309-310
Rat ventral prostate, estradiol benzoate effect
on, 369-379
Rat zona reticularis, T H C effect on, 362-363
Reproductive function, marijuana effect on,
346, 427-436, 453-467, 471-483
Reserpine, following T H C pretreatment,
819-820
Reserpine-induced hypokinesia, in Parkinson's
disease model, 816-819
Reserpine-induced monoamine depletion,
820-822
Reserpinized rats, dose response and time
course of T H C effect in, 819
Restricted reminding technique, in marijuana
use testing, 41-42
Rhesus monkey offspring, peer and maternal
social interactions in, 657-665
behavioral measures associated with
maternal drug treatment in, 661
menstrual cycle hormones in, 472-473
mother-infant bond in, 662-663
ovulation induction in, 477
pregnancy outcomes in, 658
907
S
Salmonella typhimurium mutants
characteristics of, 753-754
response to THC, 751 -773
SAR, see Structure-activity relationships
Seminal vesicle, cytological observations of,
359-379
Semisynthetic cannabinoids, triglyceride/
phospholipid partitioning and pharmaco-
kinetics of, 709-725
SOD, see Superoxide dismutase
Sodium/potassium excretion, in dogs,
739-748
Solid phase synthesis, in cannabinoid analysis,
158-159
Somatosensory-evoked potential, T H C and,
625-626
Spermatogenesis
arginine and, 672
cannabinoid effects on, 427-436
Spermatogenic cell separation and culture,
cannabinoids and, 430-431
3
H-Spiroperone binding, measurement of,
577-586
Stria terminalis sections, T H C effects in,
511-513
Striatum inactivation, potassium chloride
induction of, 823-827
Structure-activity relationships, in cannabin-
oids, 74-76
7-Substituted delta-1-THCs, synthesis of, 72
Suckling-induced prolactin secretion, T H C in-
hibition of, 487-494
Superoxide dismutase
N B T reduction inhibition by, 332-336
nitro blue tetrazolium reduction inhibition
by, 321
superoxide radical generation and, 319-325
Superoxide radicals
ethanol and, 319-325
nonenzymatic production of, 330
toxicity of, 329
Synthetic cannabinoids, dissociation of
psychotropic and analgetic effects in,
780-784
Syva EMIT system, in T H C urinalysis,
123-132, 274-275, 278, 281-289
Τ
Tachyphylaxis, in T H C tolerance, 171
Teratogenesis, cannabinoids and, 420
908
Testosterone levels
cannabinoids and, 414-415
PCP and, 444
Testosterone propionate implants, in male
rats, 404-407
1-Tetrahydrocannabinol, steric formula for,
711
7-Tetrahydrocannabinol, steric formula for,
711
Δ-1 -Tetrahydrocannabinol
absorption of by smoking, 239-242
acid metabolites in urinary excretion of,
211-217
analgesia and, 13, 780-781
pharmacokinetics of, 165-182
psychotropic effects of, 709-725
Δ-6-Tetrahydrocannabinol, psychotropic
effects of, 709-725
Δ-8-Tetrahydrocannabinol, structure of, 550
Δ-8-Tetrahydrocannabinol analogs, pharma-
cological activity of, 531-532
Δ-9-Tetrahydrocannabinol, see also Cannabis;
Cannabinoids; Marijuana
absorption of in smoking, 239-242
absorption spectrum of in ethanol, 330-332
acidic metabolites of, in human urine,
214-215
afferent input and, 855
antiemetic properties of, 859-869
autonomic effects of, 635-647
behavioral effects of, 523-524, 527
beta-adrenergic receptor and, 591-600
blood pressure and, 636
bradycardia and, 635
from carene oxides, 68
central excitatory and depressant properties
of, 845
chemical formula for, 187
cholesterol and, 681-682
from chrysanthenol, 66-67
CNS excitation from, 851
in complete hypothalamic deafferentation,
507-509
cortical sensory evoked activity and,
3
621-631
in H - D N A binding, 593-598
in diagonal band of Broca sections, 511
discriminative stimulus properties of,
545-559
distribution and disposition of in rat
tissues, 309-316
in dog fractional sodium and potassium
excretion, 739-748
Index
in dorsal longitudinal fasciculus sections,
513
eleven-hydroxy metabolite of, 529-531
excretion of, 123-132, 192-198,21 1-217,
263-268, 282-283
and female rat prolactin lines, 497-518
frontal suprachiasmic cuts and, 509
and FSH/LH levels, 472-475
in herpes simplex virus replication, 891 -898
"high" from, 191, 245-248
in human feces, 198-200
hypotension and, 635, 730-731, 822-83
immunological defects and, 682-683
interaction with other cannabinoids, 177
isolation and synthesis of, 245
in lateral corticohypothalamic tract
sections, 510
as lipophilic drug, 466
in marijuana cigarettes, 101-106
membrane-associated systems in, 591
from p-menthadienol, 67-68
from p-menthe-2-ene-l,8-diol, 68
metabolic rate of, 246
metabolic pathways for, 213
metabolism of, 123, 185-208, 213
metabolites of, 69-74
in mice, 291-295, 302-303, 345-353,
563-572
in mouse embryonic development, 345-353
in mouse reactivity and food intake,
563-592
mutagenic potential of, 682-685
neurotransmitter uptake systems and, 591
objective and subjective effects of, 829-831
opioid activity augmentation by, 788-790
oxepine derivatives of, 529
in Parkinson's disease model, 815-827
PCP and, 444-450
plasma levels and, 169-170, 174, 177- 182
pentafluorobenzylation of, 158-159
pharmacokinetic and statistical analysis of,
188-189, 198-203
pharmacokinetics of, following intravenous
and oral administration, 227-237
plasma levels of, 177-182, 189-195,205,
222, 229-231, 293
postnatal mortality and, 487-488
in presuprachiasmatic cuts, 509-510
primate menstrual cycle and, 478-482
prostaglandin stimulation by, 729-736
psychological effects of, 187-188
in rabbits, 294-304
rat nucleus accumbens and, 649-654
Index
in rat reproductive development and func- 11-ΟΗ-Δ-8-Tetrahydrocannabinol, 552-554
tion. 385-396
and rat seminal vesicle or prostate, 359-379 THC, ser Δ-9-Tetrahydrocannabinol
rat testis and. 385-396
reproductive function and, 427-436,
453-467. 471-483
reserpine and, 816-819
in rhesus monkey offspring social interac-
tion. 657-665
Salmonella typhimurium mutant response
to, 751-753
side-chain hydroxylated metabolites of, 527
somatosensory-evoked potential and,
625-626'
steady-state blood levels and, 126-127
storage of. 328
in stria terminalis sections, 511-513
structure of, 549-550
in suckling-induced prolactin secretion,
487-494
superoxide dismutase inhibition by,
327-340
superoxide radical generation and, 319-340
systemic availability of, 173-177
synthesis of, 64-69
testosterone levels and, 444-450
in tissues, 293
tolerance to, 171, 471-483
urine concentration and excretion of,
196-197, 206,211-217, 263-278,
282-283
from verbenol, 65
Δ-9-Tetrahydrocannabinol analogs, pharma-
cological activity of, 530
Δ-9-Tetracannabinol high, 193, 245-253
Δ-9-Tetracannabinol metabolites, radioimmu-
noassay for, 135-148
Δ-9-Tetracannabinol-seizure susceptible
rabbits, developmental effects in, 829 - 840
11-ηοΓ-Δ-8-Tetrahydrocannabinol, 554
909
1 1-ΟΗ-Δ-9 Tetrahydrocannabinol, 552
(-)-3.4-Trans-delta-1 -tetrahydrocannabinol,
synthesis of, 63-69
Treatment Outcome Prospective Study, 50-51
Triglyceride/phospholipid partnering,
709-725
U
Ultraviolet light, superoxide radical generation
and, 320-325
3
[]-Uridine, acid soluble and insoluble
incorporation of, 432-435
Uridine metabolism, cannabinoid effects on,
430-434
Urinalysis screening, in marijuana use
detection, 123-132, 274-275, 278,
281-289
Urinary excretion
of cannabinoids, 211-217, 232-234,
263-278, 282-283
daily total positive values in, 270
of radiolabeled cannabinoids, 232-234 -
of T H C and metabolites, 192-198,214-215
V
Verbenol, T H C from, 65-66
Virus cytopathic effect, in primary human
epithelium, 893
W
Wide-angle glaucoma, cannabis in, 875